The therapy of multidrug-resistant Gram-positive, Gram-negative, and
Candida auris is challenging and has emerged as a major threat to human health.
Commonly used drugs have become increasingly resistant, which has led to an absence
of reliable options and use of current agents in combination. While this has led to the
development of newer drugs, most of them are not available in the United States or are
yet to be approved by the FDA. Described here is a comprehensive overview of
antimicrobial resistance and recent developments in therapy for methicillin-resistant
Staphylococcus aureus, vancomycin-resistant Enterococcus spp, extended-spectrum β-
lactamases (ESBL's), carbapenemase-producing Enterobacteriaceae (CRE), multi-drug
resistant Pseudomonas aeruginosa (PSA), multi-drug resistant Acinetobacter (ACB),
and Candida auris.
Keywords: AmpC, Antimicrobial resistance, Candida auris, Carbapenemaseproducing
Enterobacteriaceae (CRE), Enterococcus spp, Extended-spectrum β-
lactamases (ESBL`s), Gram-negative, Gram-positive, Multidrug resistance, Multidrug
resistant Acinetobacter, Pseudomonas aeruginosa, Staphylococcus aureus.
